Inactive Instrument

Apricus Biosciences Inc Nasdaq

US03832V1098

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

16/05	Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	CI
14/05	Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	MT

Apricus Bioscience Inc : Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa™ for Onychomycosis

January 04, 2012 at 12:17 am IST

MarketScreener.com By

Apricus Bio Can Receive Up to Approximately $8 Million (Canadian) Plus Tiered Double Digit Royalties Under Multi-year Agreement

Stellar Pharma Strengthens Its Dermatology Business in Canada With Its Second Prescription Product, MycoVa

Latest news about Apricus Biosciences Inc

Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	16/05	CI
Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	14/05	MT
Seelos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Seelos Therapeutics, Inc. Announces Resignation of Daniel J. O?Connor from the Board	04/05	CI
Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors	29/04	CI
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	19/03	MT
Seelos Therapeutics' ALS treatment fails in mid-stage study	19/03	RE
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)	19/03	CI
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	04/03	MT
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	04/03	MT
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement	26/01	MT
Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002	22/01	CI
Certain Warrants of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	13/01	CI
Certain Stock Options of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	13/01	CI
Certain Common Stock of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	13/01	CI
Sector Update: Health Care Stocks Gain Premarket Tuesday	19/12	MT
Seelos Therapeutics Files $250 Million Mixed Shelf	19/12	MT
Seelos Therapeutics, Inc.(NasdaqCM:SEEL) dropped from S&P Global BMI Index	18/12	CI
Seelos Therapeutics Insider Bought Shares Worth $100,223, According to a Recent SEC Filing	02/12	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	30/11	MT
Sector Update: Health Care	30/11	MT
Top Midday Decliners	30/11	MT
Top Premarket Decliners	29/11	MT
Seelos Therapeutics Prices Common Stock Offering	29/11	MT

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.

Sector

Biotechnology & Medical Research

Calendar

02/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs

Apricus Biosciences Inc Nasdaq

Equities

US03832V1098

Biotechnology & Medical Research

Apricus Bioscience Inc : Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa™ for Onychomycosis

Latest news about Apricus Biosciences Inc

Chart Apricus Biosciences Inc

Company Profile

Sector Bio Therapeutic Drugs